CanadaBis Capital With its wholly owned Sub. (STIGMA GROW) Announces Revenue Q2 F2025 Resulting in $9M Gross with $96k in NET Earnings and an Adjusted EBITDA of $434,158.00
CanadaBis Capital Reports Strong Q2 Financial Results with $9M in Gross Revenue and $434,158 Adjusted EBITDA
CALGARY AB, March 31, 2025 /CNW/ - CanadaBis Capital Inc. ("CanadaBis" or the "Company") (TSXV: CANN), a leading player in the cannabis sector, is pleased to announce its financial results for the second quarter of 2025, ending January 31, 2025.
For Q2 2025, the Company reported gross revenue of $9,000,000, a significant increase of approximately $2,000,000 compared to the same period in the previous year. This represents strong year-over-year growth in line with CanadaBis's ongoing efforts to scale operations and optimize its portfolio of assets in the expanding cannabis market.
- Gross Revenue: $9,000,000, an increase of approximately $2M from Q2 2024.
- Adjusted EBITDA: $434,158, reflecting continued operational efficiency and cost-control initiatives.
- Net Revenue: $96,000, demonstrating strong fundamentals and effective business development strategies.
"Our Q2 results showcase the continued momentum in our operations as we focus on growing revenue and optimizing margins across our portfolio," said Travis McIntyre, CEO of CanadaBis Capital. "The increase in gross revenue of approximately $2M year-over-year is a testament to the hard work and strategic initiatives we've undertaken to strengthen our position in the market. We remain focused on delivering shareholder value through growth and operational excellence."
The Company initiated additional cost-saving measures during Q2 2025 by renegotiating input material pricing and implementing new procedures in its production lines to reduce and manage operational costs. Management expects these initiatives to deliver measurable benefits throughout 2025.
As a vertically integrated cannabis company, CanadaBis Capital will continue to adjust its internal strategy based on external factors, including fluctuations in product/service pricing and input costs. This approach aims to optimize capacity allocation for the highest-demand products and services while maintaining mandated gross profit margins.
Management notes that the current cannabis industry climate is highly competitive and saturated with multiple products across the nation. However, CanadaBis holds several competitive advantages to ensure long-term success. In the short term, the Company's key differentiator is its butane hydrocarbon (BHO) extraction process, which offers unique efficiencies and product quality. Management continues to explore new concentrate products to diversify its market offerings by formulating innovative products to meet evolving consumer demand.
About CanadaBis Capital Inc.
CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the global cannabis market – with specific attention paid to supplying the fast-emerging concentrates category through their Stigma Grow cultivation and BHO extraction facility.
Subsidiaries:
- Stigma Pharmaceuticals Inc. – 100% held;
- 1998643 Alberta Ltd. (operating as "Stigma Grow") - 100% held; include cultivation and wholesale, extraction and tolling
- Full Spectrum Labs Ltd. (operating as "Stigma Roots") - 100% held;
- 2103157 Alberta Ltd. -100% held; the retail brick and mortor
- Goldstream Cannabis Inc. - 95% held.
Acting as the cornerstone for everything they offer, Stigma Grow continuously strives to address the market demands and lingering stigmas within the legal cannabis industry head-on, with products designed to disturb the status quo and dramatically shift the conversation surrounding Canada's legal cannabis industry.
For more information on CanadaBis Capital or Stigma Grow visit:
www.canadabis.com
www.stigmagrow.ca
CAUTIONARY STATEMENT
Non-GAAP Measures
This news release contains the financial performance metric of Adjusted EBITDA, a measure that is not recognized or defined under IFRS (a "Non-GAAP Measure"). As a result, this data may not be comparable to data presented by other cannabis companies. For an explanation and reconciliation of Adjusted EBITDA to related comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to the MD&A for the three and six months ended Oct 31, 2024. The Company believes that Adjusted EBITDA is a useful indicator of operational performance and is specifically used by management to assess the financial and operational performance of the Company.
Adjusted EBITDA is a measure of the Company's financial performance. It is intended to provide a proxy for the Company's operating cash flow and is widely used by industry analysts to compare CanadaBis to its competitors and derive expectations of future financial performance of the Company. Adjusted EBITDA increases comparability between comparative companies by eliminating variability resulting from differences in capital structures, management decisions related to resource allocation, and the impact of fair value adjustments on biological assets, inventory, and financial instruments, which may be volatile on a period-to-period basis. Adjusted EBTIDA is not a recognized, defined, or standardized measure under IFRS. The Company calculates Adjusted EBITDA as net income (loss) and comprehensive income (loss) excluding changes in fair value of biological assets, change in fair value of biological assets realized through inventory sold, depreciation and amortization expense, share-based payments, and finance costs.
REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include but are not limited to statements with respect to our business and operations; timing of the Sundial products coming to market; the demand and market for live-resin vape cartridges, and our general business plans. Forward-looking statements are necessarily based upon a number of assumptions including: the ability of the Company's products to compete with the pricing and product availability on the black-market; the market demand for the Company's products; and assumptions concerning the Company's competitive advantages. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; ability to sustain or create a demand for a product; requirement for further capital; delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Company's continuous disclosure on SEDAR at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE CanadaBis Capital Inc.
Travis McIntyre CEO, [email protected]; Investor Relations, [email protected], 1-888-STIGMA1
Share this article